摘要
目的:探析伯乐酶联仪检测血清GP73和GPC3在肺部肿瘤早期诊断及临床应用价值。方法:选择研究对象为2015年6月~2016年6月时间段中来我院就诊的30例肺癌患者,为A组,30倒良性肿瘤患者为B细.同时再抽选同一时间段中我院接诊30例健康体检患者,为对照组,通过酶联免疫吸附法检测患者血清中的GP73、GPC3等肿蓿标志物,统计对比三组患者的检测结果。结果:A、B两组患者的GP73检测结果分别是(361.96±17.34)ng/mL、(120.79±12.47)ng/mL,对照细是(11.67±5.62)ng/ml,组间比较的差异性显著(P〈0.05),且A组与B组的组问比较的差异性显著(P〈0.05)。A、B两组患者的GPC3检测结果分别是(424.89±74.321ng/1、(90.23±17.08)ng/1,对照组是(29.56±9.41I)ng/L,组间比较的差异性显著(P〈0.05).且A组与B组的细间比较的差异性显著(P〈0.05),结论:GP73和GPC3在肺肿瘤的早期诊断中的应用,有利于患者临床诊断的开展,提高患者的临床诊断准确率,及时进行有效治疗.大大降低患者的死亡率,延长患者的生存时间.提高患者的生活质量。
Objective:By analyzing the cause of deficiency during the evaluation of the manufacturer of 77 In Vitro Diagnosis(IVD)reagent,provide the IVD reagent manufacturer and inspector with reference on points for attention.Methods:Statistical analysis on the deficiency of inspected manufacturer after the execution of Regulation of Quality Evaluation of IVD Reagent Manufacturer(Test).Results:Among the 766 deficiencies evaluated on 77 IVD reagent manufacturer,127 causes is covered,accounting for 82%.Conclusion:Focus on the analysis of causes for deficiency,improve the quality of IVD reagent,increase the percent of pass of system evaluation and efficiency of inspector.
出处
《中国医疗器械信息》
2016年第02X期10-11,共2页
China Medical Device Information